蛋白质组数据和对大脑微血管内皮细胞在不同氧气水平下的药物影响
Sarah Barakat1, Fan Yang2, Hayriye Ecem Yelkenci3
1Regenerative and Restorative Medicine Research Center (REMER), Research Institute for Health Sciences and Technologies (SABITA), Istanbul Medipol University, Istanbul, 34810, Turkey. sarah.barakat1@medipol.edu.tr.
Scientific data
|June 12, 2025
概括
标准的细胞培养使用高氧,导致氧化应激. 将细胞适应生理氧气水平 (5kPa O2) 改善了体外模型,揭示了依赖氧气的药物反应和蛋白质转移,这对研究准确性至关重要.
科学领域:
- 细胞生物学 细胞生物学
- 蛋白质组学是指蛋白质组学.
- 药物发现 药物发现 药物发现
背景情况:
- 标准的细胞培养氧气水平 (18 kPa O2) 诱导氧化应激,可能影响研究结果.
- 大脑微血管内皮细胞 (hCMEC/D3) 在体内通常会经历较低的氧气 (≤7 kPa O2).
研究的目的:
- 使用适应的hCMEC/D3细胞优化体外生理细胞培养模型.
- 为了研究氧气水平对蛋白质组形状和药物反应的影响.
主要方法:
- 适应hCMEC/D3细胞以5kPa O2为条件,持续5天.
- 使用质谱法 (SYNAPT G2-Si) 进行比较的蛋白质组形状,低于5kPa相对于18kPa O2.2.
- 在不同氧气条件下使用硫 (SFN) 评估药物查反应.
主要成果:
- 在5kPa和18kPa O2之间观察到显著的蛋白质转移,表明氧气对蛋白质表达的影响.
- 硫福拉在高氧 (18 kPa O2) 状态下诱导的蛋白质变化比生理氧 (5 kPa O2) 更明显.
- 细胞对药物的反应取决于氧气水平.
结论:
- 将细胞适应生理氧气水平,可以创建一个更相关的体外模型.
- 氧气水平显著影响蛋白质组形状和药物疗效.
- 这些发现有助于开发与生理氧气条件一致的疗法.
相关概念视频
The Blood-brain Barrier
Overview
Physiological Barriers
Physiological barriers are semi-permeable cellular structures restricting drug diffusion into intracellular compartments and tissues. There are six types of physiological barriers: blood endothelial, cell membrane, blood-brain, blood-cerebrospinal fluid (CSF), blood-placenta, and blood-testis barriers.
The blood endothelial barrier is the most porous of these. It allows all small ionized, un-ionized, and lipophilic molecules to pass through the endothelial lining into the interstitial space...
The blood endothelial barrier is the most porous of these. It allows all small ionized, un-ionized, and lipophilic molecules to pass through the endothelial lining into the interstitial space...
Factors Affecting Drug Distribution: Tissue Permeability
The drug distribution process within the human body is a complex interplay of various physicochemical properties inherent to the drugs. These properties, including molecular size, ionization degree, partition coefficient, and stereochemical nature, significantly impact how drugs permeate biological membranes to reach their target tissues.
Small molecules with a molecular weight below 500 to 600 Daltons can easily pass through the capillary membrane, gaining access to different tissues. Larger...
Small molecules with a molecular weight below 500 to 600 Daltons can easily pass through the capillary membrane, gaining access to different tissues. Larger...
Drug Binding to Blood Components
When drugs enter systemic circulation, they interact with various components of the blood, including proteins such as human serum albumin (HSA), α1-acid glycoprotein (AAG), lipoproteins, globulins, and red blood cells (RBCs).
HSA is the most abundant plasma protein and is vital in drug binding. It contains distinct drug-binding sites, with different drugs exhibiting affinity for specific sites. There are three main drug-binding domains for HSA: sites I, II, and III. These domains are further...
HSA is the most abundant plasma protein and is vital in drug binding. It contains distinct drug-binding sites, with different drugs exhibiting affinity for specific sites. There are three main drug-binding domains for HSA: sites I, II, and III. These domains are further...
Factors Affecting Protein-Drug Binding: Protein-Related Factors
Drug binding to proteins is a key aspect of pharmacokinetics and can influence a drug's distribution, absorption, and elimination in the body. Several factors, including the drug's physiochemical properties, protein concentration, disease states, and the number of binding sites on the protein, influence this process.
The physicochemical properties of a drug play a significant role in its ability to bind to proteins. Lipophilic drugs, which dissolve in fats, oils, and lipids, can be bound by...
The physicochemical properties of a drug play a significant role in its ability to bind to proteins. Lipophilic drugs, which dissolve in fats, oils, and lipids, can be bound by...
Factors Affecting Protein-Drug Binding: Patient-Related Factors
Protein-drug binding, a pivotal aspect of pharmacokinetics, is subject to considerable variability influenced by an array of patient-related factors. The intricate interplay of age, individual differences, and pathological conditions significantly impact the binding dynamics and subsequent pharmacological effects.
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...


